INTRODUCTION: The National Cancer Comprehensive Network (NCCN) has advised vaccination against COVID-19 in all patients undergoing chemotherapy and immunotherapy. There is limited data on how cancer-targeted therapies impact COVID-19 vaccination in this population and determining its efficacy necessitates close study. Methods: This study is measuring both qualitative and quantitative serum neutralizing antibodies (NAb) against the SARS-CoV-2 spike protein, nucleocapsid, and receptor binding domains in patients undergoing cancer-targeted therapies. NAb assays are also being performed for SARS-CoV-2 variants: UK (B.1.1.7), SA (B.1.351), and Brazil (P.1). Serum was collected prior to vaccination and continues to be drawn after vaccination at months: 1, 3, 6, and 12. Results: This study has accrued 136 patients to date with both solid and hematologic malignancies undergoing cancer-targeted therapies. While data collection is ongoing for the majority of patients, interim analysis does reveal that prior to their third vaccine dose the majority of patients receiving therapies for B-cell malignancies have a blunted response, anthracycline based chemotherapies suppress vaccine responses in about half of patients, and immunotherapy alone does not appear to negatively impact vaccine efficacy. Results assessing both patient response to vaccination and its durability up to 6 months will be available for the majority of patients at time of presentation. Discussion/Conclusions: While receiving cancer-targeted therapies, patients are at increased risk for developing fatal COVID-19 infections due to their immunosuppression. While the NCCN initially advised vaccination without regard to timing nor type of therapy received, there remains limited data on how such therapies impact COVID-19 vaccination in a general medical oncology clinic. This study will highlight not only the response to vaccination but also durability in patients receiving multiple oncologic therapies across a spectrum of malignancies. Furthermore, it has the potential to determine the efficacy of the third vaccine, timing of that vaccination, or in which oncologic populations COVID19 vaccination may be ineffective.